Physician profile
Kyle Bensinger
NPI 1235547209
$624.49
in general payments reported to CMS, 2019-2025
13 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2021: $109 · 2022: $170 · 2023: $47.21 · 2024: $33.85 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.24 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $83.21 | 2019-2022 | |
| Coopervision INC. | $78.97 | 2019 | |
| Oyster Point Pharma, INC. | $66.60 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $64.44 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.40 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $28.02 | 2023-2025 | Xiidra, Miebo, Lotemax |
| Aerie Pharmaceuticals, INC. | $26.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.47 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $19.98 | 2025 | Xdemvy |
| Glaukos Corporation | $17.53 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.00 | 2022 | |
| Allergan, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Bensinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.